Clinical Evaluation of Blood‐Based Assays for Rapid Detection of Amyloid‐β Pathology in Alzheimer's Disease (CLEAR‐AD)
CLEAR-AD study provided crucial data on the effectiveness of commercially available blood biomarkers for predicting amyloid pathology and inform the optimization of early AD screening in the Chinese population. The findings will guide future developments in diagnostic tools.
Authors
- Hongyi Yan (ORCID: https://orcid.org/0000-0001-5190-6345)
- Fei Gao (ORCID: https://orcid.org/0000-0002-1546-4364)
- Qianhua Zhao
- Xiaochun Chen (ORCID: https://orcid.org/0000-0002-9228-0198)
- Haining Zhang (ORCID: https://orcid.org/0000-0002-4367-4369)
- Yong Shen
- Mengya Xing
- Qidong Chen
- Yiming Wang (ORCID: https://orcid.org/0009-0004-5510-2175)
- Huayan Liu
- Xinyi Lyu
- Guoping Peng
- Fang Xie
- Jiong Shi
- Shuting Z
- Zengshi Lin
- Xiaodong Pan
- Wei Chen
Institutions
- University of Science and Technology of China (CN)
- Fujian Medical University (CN)
- Capital Medical University (CN)
- Jilin University (CN)
- Sichuan University (CN)
- Fudan University (CN)
- Sir Run Run Shaw Hospital (CN)
- Tianjin Medical University General Hospital (CN)
- Beijing Tian Tan Hospital (CN)
- SAIC-GM (China) (CN)
- First Hospital of Jilin University (CN)
- First Hospital of China Medical University (CN)
- Huashan Hospital (CN)
- Union Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_100197
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00